Clinical Trial Update: Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating Zanzalintinib plus nivolumab for locally advanced or inoperable clear cell renal cell carcinoma (with or without non-meas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Zanzalintinib (Zanzalintinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Qian Qin | Conditions: Locally Advanced Renal Cell Carcinoma | Phase 2 | Status: RECRUITING